Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Non-Hodgkin Lymphoma

Making It Personal With Waldenstrom's Macroglobulinemia

Beth Fand Incollingo

Treating relapsed Waldenstrom’s macroglobulinemia takes an individualized approach from a growing list of options.

CURE's Top 5 Stories: July 2019

Jessica Skarzynski

Here are the top 5 CURE stories for July 2019.

What Being a Survivor Means to 'The Pink Hulk', a Three-Time Cancer Survivor

Valerie David

Three-time cancer survivor and one-woman show writer and performer, Valerie David, sat down with CURE® to discuss life as a survivor.

Blending the Truth With Compassion in Cancer Care

Jerry Bridges, M.S.N., RN, CNP

This essay describes my journey with non-Hodgkin lymphoma — peripheral T-cell, not otherwise specified — and my most extraordinary nurse, Xuan Arnette, RN, OCN.

Friday Frontline: Cancer Updates, Research and Education on July 26, 2019

Alexandra Guadagno

From landmark Senate legislation to the Pink Lemonade Stand Challenge, here’s what is making headlines in the cancer space this week.

FDA Approves Biosimilar Ruxience: Here's What You Need to Know

Kristie L. Kahl

With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.

FDA Approves Rituxan Biosimilar to Treat Blood Cancers

Jessica Skarzynski

The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.

Future Management of Waldenstrom Macroglobulinemia

Following a discussion on the multidisciplinary management of Waldenström Macroglobulinemia, Steven P. Treon, MD, PhD, reflects on the future management of this disease.

BTK Inhibitors in WM: Understanding Safety/Efficacy

Steven P. Treon, MD, PhD, provides insight on balancing safety and efficacy while treating Waldenström macroglobulinemia with BTK inhibitors.

Targeted Approaches in Waldenstrom Macroglobulinemia

Key opinion leader Steven P. Treon, MD, PhD, reviews the advent of targeted therapy for patients with Waldenström macroglobulinemia.

Non-Hodgkin Lymphoma

Sign In